间皮素作为癌症免疫治疗的生物标志物和治疗靶点
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.
癌症仍是一个关键的全球健康问题，原因在于发现晚、耐药和高死亡率。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胃癌的细胞免疫治疗：过继性细胞治疗和基于树突状细胞的疫苗
英文原题：Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination.
查看英文原题
Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胃癌（GC）是最常被诊断的恶性肿瘤之一。近期研究强调细胞免疫治疗（CI）是治疗该疾病的一种有前景的方法。在基于CI的方法中，过继细胞治疗和基于树突状细胞的疫苗在临床前和临床试验中常被研究。在此，我们综述了关于CI治疗GC潜力的当前证据、过继细胞治疗的靶点、正在进行的临床试验、限制因素以及未来展望。结果表明，有必要识别能够预测哪些GC患者最可能对这些方法产生应答的新型生物标志物。此外，CI联合化疗或免疫检查点抑制剂可以提高晚期GC患者的生存率。因此，这种方法对于治疗这些患者可能是有前景的。
展开英文摘要原文
Gastric cancer (GC) is one of the most frequently diagnosed malignancies. Recent studies have highlighted cellular immunotherapy (CI) as a promising approach for treating this disease. Among the CI-based approaches, adoptive cell therapy and dendritic cell-based vaccination are commonly studied in preclinical and clinical trials.
Here we review the current evidence on the potentiality of CI in treating GC, the targets for adoptive cell therapy, ongoing clinical trials, constraints and the future outlook. The results suggest that there is a need to identify novel biomarkers that predict which GC patients will most likely respond to these approaches. Also, CI plus chemotherapy or immune checkpoint inhibitors can improve the survival of patients with late-stage GC.
Therefore, this approach can be promising for treating these patients.
论文信息
- 作者
- Faghfuri E、Shadbad MA、Faghfouri AH、Soozangar N
- 单位
- Digestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.Iran
- 文献类型
- 非美国政府资助研究 · 综述
- 期刊
- Immunotherapy2022 Apr
- 原文标识
- PubMed 35232264 · DOI 10.2217/imt-2021-0285